Cargando…
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
Fifteen monoclonal antibodies (mAbs) are currently registered and approved for the treatment of a range of different cancers. These mAbs are specific for a limited number of targets (9 in all). Four of these molecules are indeed directed against the B-lymphocyte antigen CD20; 3 against human epiderm...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827071/ https://www.ncbi.nlm.nih.gov/pubmed/24251081 http://dx.doi.org/10.4161/onci.26333 |